Floatz logo

Linsitinib

Pharmacokinetics of 14C-OSI-906

Astellas Pharma Global Development, Inc.Small moleculePhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
31/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Pharmacokinetics of 14C-OSI-906 cohort.

Asset / SponsorPhaseRating

Same molecule, other indications

Linsitinib is also rated in:

small cell lung carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →
prostate adenocarcinomaDormant
CCC
Indicative ·
52 / 100
View asset →
hormone-resistant prostate carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →